UNSPSC 51293614: Pirlindole hydrochloride

This classification denotes a monoamine oxidase inhibitor C15H18N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q89W8I397C, chemically known as 1h-pyrazino(3,2,1-jk)carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-, hydrochloride (1:1), but more generally known as pirlindole hydrochloride, which bears US NIH Compound Identifier 115141. European Medicines Agency schedules Pirlindole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35547.

Most nations, for tariff and trade purposes, schedule pirlindole hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, PIRLINDOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCC2C(C1)C3C4N2CCNC4CCC3.CL.

UNSPSC 51293614 Pirlindole hydrochloride is a Commodity code that in recent state and local procurement activity refers to pharmaceutical products and related health-system supplies rather than the specific active pharmaceutical ingredient its name suggests. State and local buyers—county health departments, state health and human services agencies, and cooperative purchasing alliances—use this code and related pharmaceutical commodity codes to procure naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and request-for-proposal processes. The work includes establishing supply contracts for pharmaceutical inventory, negotiating pricing with manufacturers and authorized wholesalers, and managing quarterly or ongoing deliveries to health facilities and community programs. Issuing bodies span county public health divisions, state health and human services departments, and multistate cooperative purchasing organizations that aggregate demand across multiple jurisdictions and member agencies.

Recent activity centers on Florida and Minnesota, with broader multistate coordination through cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year contract with one-year renewal option, with quarterly deliveries due by July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and July 1, 2026 contract effectiveness, requiring authorized wholesale distribution through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance, cGMP certification, and DSCSA compliance.